Iron Metabolism Disease (IRON)

Categories: Blood diseases, Metabolic diseases, Respiratory diseases

Aliases & Classifications for Iron Metabolism Disease

MalaCards integrated aliases for Iron Metabolism Disease:

Name: Iron Metabolism Disease 12 15
Iron Deficiency 74 54 71 32
Iron Metabolism Disorders 43 71
Iron Disorder 12 54
Disorder of Iron Metabolism 12
Iron 42


External Ids:

Disease Ontology 12 DOID:2351
ICD9CM 34 275.0
MeSH 43 D019189
SNOMED-CT 67 30913008
ICD10 32 E61.1 E83.1
UMLS 71 C0012715 C0240066

Summaries for Iron Metabolism Disease

MedlinePlus : 42 Iron is a mineral that our bodies need for many functions. For example, iron is part of hemoglobin, a protein which carries oxygen from our lungs throughout our bodies. It helps our muscles store and use oxygen. Iron is also part of many other proteins and enzymes. Your body needs the right amount of iron. If you have too little iron, you may develop iron deficiency anemia. Causes of low iron levels include blood loss, poor diet, or an inability to absorb enough iron from foods. People at higher risk of having too little iron are young children and women who are pregnant or have periods. Too much iron can damage your body. Taking too many iron supplements can cause iron poisoning. Some people have an inherited disease called hemochromatosis. It causes too much iron to build up in the body. Centers for Disease Control and Prevention

MalaCards based summary : Iron Metabolism Disease, also known as iron deficiency, is related to neurodegeneration with brain iron accumulation 3 and congenital dyserythropoietic anemia. An important gene associated with Iron Metabolism Disease is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Glucose / Energy Metabolism. The drugs Edoxaban and Rivaroxaban have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Iron deficiency, or sideropenia, is the state in which a body lacks enough iron to supply its needs.... more...

Related Diseases for Iron Metabolism Disease

Diseases related to Iron Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2004)
# Related Disease Score Top Affiliating Genes
1 neurodegeneration with brain iron accumulation 3 33.8 SLC11A2 IREB2 FTL CP ACO1
2 congenital dyserythropoietic anemia 32.7 TFRC HFE HAMP EPO
3 hemochromatosis, type 5 32.3 TFR2 HJV HFE FTL ACO1
4 anemia, congenital dyserythropoietic, type ia 32.3 TFRC HJV HAMP EPO
5 hemochromatosis, type 2b 32.0 HAMP FTL
6 restless legs syndrome 32.0 TFRC SLC11A2 IREB2 FTL EPO ACO1
7 atransferrinemia 31.8 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
8 hemochromatosis, type 3 31.8 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
9 hemochromatosis, type 2a 31.6 TFR2 SLC40A1 HJV HFE HAMP
10 hemochromatosis, type 4 31.2 TFR2 SLC40A1 SLC11A2 HJV HFE HEPH
11 iron overload in africa 30.8 TFR2 TF SLC40A1 HJV HFE HEPH
12 iron-refractory iron deficiency anemia 30.6 HJV EPO
13 sickle cell disease 30.6 HBB HBA2 EPO
14 arthropathy 30.6 HJV HFE HAMP CRP
15 end stage renal disease 30.5 HFE EPO CRP
16 neutropenia 30.2 TFRC EPO CRP CP
17 eales disease 30.2 TF CP
18 erythrocytosis, familial, 2, autosomal recessive 30.1 EPO CYBRD1 ACO1
19 sickle cell anemia 30.1 HBB HBA2 EPO CRP
20 pulmonary tuberculosis 30.1 SLC11A1 CRP CP
21 alpha-thalassemia 30.0 TFRC HFE HBB HBA2 EPO
22 red cell aplasia 30.0 TF EPO
23 nutritional deficiency disease 30.0 TFRC TF HJV HAMP EPO CRP
24 erythroleukemia, familial 30.0 HBB EPO
25 polycythemia 30.0 TFRC HBB HBA2 HAMP EPO
26 alpha-1-antitrypsin deficiency 29.9 IREB2 HFE HAMP
27 anemia of prematurity 29.9 HAMP EPO
28 protoporphyria, erythropoietic, 1 29.9 TFRC IREB2 ACO1
29 acquired polycythemia 29.9 HAMP EPO
30 anemia, sideroblastic, 1 29.9 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
31 analbuminemia 29.8 TF EPO CRP
32 viral hepatitis 29.8 HFE CRP CP
33 hydrops fetalis, nonimmune 29.8 HBB HBA2
34 wilson disease 29.8 TFRC TF SLC11A2 HFE CP
35 neonatal anemia 29.8 HBA2 EPO
36 splenic sequestration 29.8 HBB EPO
37 brucellosis 29.7 SLC11A1 HAMP CRP
38 aceruloplasminemia 29.6 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
39 folic acid deficiency anemia 29.5 TFRC HAMP EPO CRP
40 asphyxia neonatorum 29.5 EPO CRP
41 visceral leishmaniasis 29.4 SLC11A1 HAMP CRP
42 hemochromatosis type 2 29.4 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
43 extrapulmonary tuberculosis 29.4 SLC11A1 HAMP CRP
44 hemoglobinopathy 29.3 TFRC TFR2 TF HJV HFE HBB
45 hemosiderosis 29.2 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2
46 hemochromatosis, type 1 29.2 TFRC TFR2 TF SLC40A1 SLC11A2 MT-CYB
47 buruli ulcer 29.2 SLC11A1 HBB
48 hemolytic anemia 29.1 TFRC TF HBB HBA2 EPO
49 malaria 29.1 TFRC MT-CYB HBB HBA2 HAMP EPO
50 friedreich ataxia 29.1 TFRC SLC40A1 SLC11A2 IREB2 HFE HAMP

Comorbidity relations with Iron Metabolism Disease via Phenotypic Disease Network (PDN):

Deficiency Anemia Pulmonary Hemosiderosis

Graphical network of the top 20 diseases related to Iron Metabolism Disease:

Diseases related to Iron Metabolism Disease

Symptoms & Phenotypes for Iron Metabolism Disease

MGI Mouse Phenotypes related to Iron Metabolism Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 CP EPO FTL HBA2 HEPH HFE
2 homeostasis/metabolism MP:0005376 10.16 ACO1 CP CRP CYBRD1 EPO FTL
3 cardiovascular system MP:0005385 10.07 CP CRP CYBRD1 EPO HEPH HJV
4 immune system MP:0005387 10 CP CRP EPO FTL HEPH HFE
5 integument MP:0010771 9.56 EPO HBA2 HEPH HJV IREB2 SLC11A2
6 liver/biliary system MP:0005370 9.4 CP CYBRD1 EPO FTL HEPH HFE

Drugs & Therapeutics for Iron Metabolism Disease

Drugs for Iron Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 664)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Edoxaban Approved Phase 4 480449-70-5
Rivaroxaban Approved Phase 4 366789-02-8
Apixaban Approved Phase 4 503612-47-3 10182969
Nevirapine Approved Phase 4 129618-40-2 4463
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
Lumefantrine Approved Phase 4 82186-77-4 6437380
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
Halofantrine Approved Phase 4 69756-53-2 37393
Ferrous gluconate Approved Phase 4 299-29-6
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Topiramate Approved Phase 4 97240-79-4 5284627
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Ribavirin Approved Phase 4 36791-04-5 37542
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
Atorvastatin Approved Phase 4 134523-00-5 60823
Ledipasvir Approved Phase 4 1256388-51-8 67505836
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
Pravastatin Approved Phase 4 81093-37-0 54687
lanreotide Approved Phase 4 108736-35-2
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
Metformin Approved Phase 4 657-24-9 14219 4091
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
Ferrous fumarate Approved Phase 4 141-01-5
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
Ferric maltol Approved Phase 4 33725-54-1
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
Choline Approved, Nutraceutical Phase 4 62-49-7 305
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Phenylalanine Approved, Investigational, Nutraceutical Phase 4 63-91-2 6140
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
Enclomiphene Investigational Phase 4 15690-57-0
50 Antiviral Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 2361)
# Name Status NCT ID Phase Drugs
1 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
2 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
3 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
4 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
5 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
6 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
7 Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
8 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
9 Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels Unknown status NCT01374776 Phase 4 Double blind, randomized, placebo controlled inter
10 Double-Blind, Single-Center Interventional Trial To Evaluate The Effect Of Intravenous Iron Versus Placebo On Cerebral Dopamine Receptor Density In Non Anaemic Premenopausal Women With Low Ferritin Levels And Fatigue Unknown status NCT03305705 Phase 4 Iron Carboxymaltose;Sodium chloride 0.9%
11 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
12 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
13 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
14 Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone Unknown status NCT02731378 Phase 4 Erythropoietins (EPO);Aggressive iron dextran supplementation;Erythropoietins (EPO);Sustained iron dextran supplementation
15 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
16 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
17 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
18 A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin. Unknown status NCT00223938 Phase 4 Oral Iron;sodium ferric gluconate;sodium ferric gluconate
19 The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
20 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
21 Predictors of Response to Treatment With Iron and Erythropoietin in Dialysis Anaemia Unknown status NCT02707757 Phase 4 Iron sucrose;Erythopoietin stimulating agent
22 A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Unknown status NCT00103753 Phase 4 deferiprone
23 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
24 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
25 Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery? Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
26 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
27 A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA Unknown status NCT02724865 Phase 4
28 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
29 The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery Unknown status NCT02939794 Phase 4 Ferinject;Placebo
30 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
31 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
32 Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy Unknown status NCT02612870 Phase 4
33 Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561506 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
34 An Open-labeled Pilot Study to Determine the Efficacy of an E2//Nomegestrol Acetate (E2/NOMAC)Combination Oral Contraceptive (COC) in the Management of Heavy Menstrual Bleeding (HMB) Unknown status NCT01715025 Phase 4 E2Nomac
35 Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study. Unknown status NCT00331656 Phase 4
36 Effect of Postoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561480 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
37 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
38 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
39 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
40 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
41 Prevention of Iron Deficiency in Breastfed Infants Completed NCT01444261 Phase 4
42 The Effect of Lactoferrin Versus Iron Supplement in Treating Iron Deficiency Anemia and Helping Weight Loss in Obese School Age Children Completed NCT04014855 Phase 4 Iron Supplement
43 Dialysis Patients' Response to IV Iron With Elevated Ferritin Completed NCT00224081 Phase 4 Sodium ferric gluconate,
44 Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g Completed NCT00558454 Phase 4 Iron
45 Randomized Double-Blind Parallel Group MultiCenter Study of the Efficacy of Two Doses of Ferrlecit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin. Completed NCT00223964 Phase 4 Ferrlecit (sodium ferric gluconate complex in sucrose injection)
46 Lactoferrin Efficacy Versus Ferrous Sulfate in Treatment of Patients With Iron Deficiency Anemia Completed NCT04267653 Phase 4 Lactoferrin Bovine;Ferrous Sulfate
47 A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency Completed NCT01453608 Phase 4 Ferinject (ferric carboxymaltose);Placebo (saline)
48 A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia Completed NCT00802139 Phase 4 venoferrum(iron sucrose);Bolgre (Iron acetyl-transferase)
49 A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Completed NCT00224055 Phase 4 Sodium Ferric Gluconate Complex in Sucrose Injection;Ferrous sulfate tablets
50 A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy Completed NCT00224042 Phase 4 Sodium Ferric Gluconate complex in sucrose;Ferrous sulfate tablets

Search NIH Clinical Center for Iron Metabolism Disease

Cochrane evidence based reviews: iron metabolism disorders

Genetic Tests for Iron Metabolism Disease

Anatomical Context for Iron Metabolism Disease

MalaCards organs/tissues related to Iron Metabolism Disease:

Kidney, Heart, Liver, Testes, Brain, Bone, Breast

Publications for Iron Metabolism Disease

Articles related to Iron Metabolism Disease:

(show top 50) (show all 19560)
# Title Authors PMID Year
Iron and hepcidin mediate human colorectal cancer cell growth. 42
32092301 2020
Iron intake is positively associated with viral load in antiretroviral naïve Brazilian men living with HIV. 42
32022169 2020
Postpartum anemia is a neglected public health issue in China: a cross-sectional study. 42
31826377 2019
Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. 54 61
20486179 2010
Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. 54 61
20410090 2010
Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. 54 61
19624802 2010
Posttransplant anemia in solid organ recipients. 61 54
20303457 2010
Ceramide in suicidal death of erythrocytes. 54 61
20502001 2010
The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. 61 54
19828835 2009
Iron stores, periodic leg movements, and sleepiness in obstructive sleep apnea. 61 54
20465018 2009
Ferric carboxymaltose in patients with heart failure and iron deficiency. 61 54
19920054 2009
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 54 61
20209848 2009
Impact of socioeconomic and health related factors on the iron status of adolescent girls from two boarding schools in Southern Benin. 61 54
20306766 2009
[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)]. 61 54
20232547 2009
Differential ferritin expression is associated with iron deficiency in coeliac disease. 54 61
19404207 2009
Transferrin and ferritin response to bacterial infection: the role of the liver and brain in fish. 54 61
19428486 2009
Influence of inflammation as measured by alpha-1-acid glycoprotein on iron status indicators among HIV-positive postpartum Zimbabwean women. 54 61
18506200 2009
Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index. 54 61
19718534 2009
Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. 54 61
18949769 2009
Abnormal brain iron homeostasis in human and animal prion disorders. 54 61
19283067 2009
Early effects on T lymphocyte response to iron deficiency in mice. Short communication. 61 54
18825318 2009
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. 61 54
19147412 2009
[Immune, inflammatory, and nutritional protein profile in children with iron deficiency in Côte d'Ivoire]. 54 61
19801348 2009
Differing expression of genes involved in non-transferrin iron transport across plasma membrane in various cell types under iron deficiency and excess. 61 54
18830567 2009
The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. 54 61
19743956 2009
Suicide for survival--death of infected erythrocytes as a host mechanism to survive malaria. 61 54
19710527 2009
Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. 54 61
18987297 2009
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. 54 61
18815282 2009
Parenteral ascorbic acid in haemodialysis patients. 61 54
18827578 2008
Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. 61 54
18974579 2008
Erythrocyte programmed cell death. 61 54
18720418 2008
Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. 54 61
18469314 2008
[Old and new iron parameters in iron metabolism and diagnostics]. 61 54
18791966 2008
Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. 54 61
18613854 2008
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. 61 54
18574241 2008
Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure. 54 61
18317758 2008
[Expression of iron regulatory protein-2 and ferritins in intestinal mucosa of rats with iron deficiency]. 54 61
18549630 2008
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. 54 61
18174266 2008
Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. 54 61
18279424 2008
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. 54 61
18029550 2008
Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. 54 61
18201677 2008
Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. 61 54
18094727 2008
Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. 54 61
18306987 2008
Prognostic value of reticulocyte hemoglobin content to diagnose iron deficiency in 6-24-month-old children. 54 61
18971604 2008
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. 54 61
18212498 2008
Potential roles of erythropoietin in the management of anaemia and other complications diabetes. 54 61
17645562 2008
The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. 61 54
18004086 2007
Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. 54 61
17510944 2007
Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. 54 61
17466092 2007
Inflammation and iron deficiency in the hypoferremia of obesity. 61 54
17438557 2007

Variations for Iron Metabolism Disease

Expression for Iron Metabolism Disease

Search GEO for disease gene expression data for Iron Metabolism Disease.

Pathways for Iron Metabolism Disease

Pathways related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
Show member pathways
2 12.34 SLC11A2 IREB2 HBB CP ACO1
Show member pathways
4 11.71 TFRC TF EPO
Show member pathways
11.7 SLC40A1 SLC11A2 SLC11A1 HEPH CP
Show member pathways
11.67 HBB HBA2 FTL
7 11.52 TFRC TF EPO CP
9 11.25 TFRC TF SLC40A1 SLC11A2 FTL CP
10 10.39 HJV HFE HAMP
11 10.3 TFRC TFR2 TF SLC40A1 SLC11A2 IREB2

GO Terms for Iron Metabolism Disease

Cellular components related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.13 TFRC TF HBB HBA2 FTL CYBRD1
2 extracellular region GO:0005576 10.11 TFRC TF HBB HBA2 HAMP FTL
3 extracellular space GO:0005615 10.02 TFRC TF HJV HFE HBB HBA2
4 cell surface GO:0009986 9.93 TFRC TF SLC11A2 HJV EPO
5 early endosome GO:0005769 9.8 TFRC TF SLC11A2 HFE
6 endosome membrane GO:0010008 9.73 TFRC TF SLC11A2 SLC11A1
7 recycling endosome GO:0055037 9.67 TFRC TF SLC11A2 HFE
8 blood microparticle GO:0072562 9.55 TFRC TF HBB HBA2 CP
9 endocytic vesicle lumen GO:0071682 9.51 HBB HBA2
10 cell GO:0005623 9.5 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
11 hemoglobin complex GO:0005833 9.48 HBB HBA2
12 basal part of cell GO:0045178 9.43 TF SLC11A2 HFE
13 haptoglobin-hemoglobin complex GO:0031838 9.4 HBB HBA2
14 HFE-transferrin receptor complex GO:1990712 9.35 TFRC TFR2 TF HJV HFE

Biological processes related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.04 TF SLC40A1 SLC11A2 SLC11A1 HFE HEPH
2 receptor-mediated endocytosis GO:0006898 9.87 TFRC TFR2 HBB HBA2
3 iron ion transport GO:0006826 9.85 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
4 acute-phase response GO:0006953 9.8 TFR2 HFE HAMP EPO CRP
5 transferrin transport GO:0033572 9.73 TFRC TFR2 TF HFE
6 response to iron ion GO:0010039 9.72 TFR2 SLC11A2 HFE HAMP CYBRD1
7 iron ion homeostasis GO:0055072 9.7 TFR2 TF SLC40A1 SLC11A2 SLC11A1 IREB2
8 osteoclast differentiation GO:0030316 9.69 TFRC TF IREB2
9 iron ion transmembrane transport GO:0034755 9.67 TF SLC40A1 SLC11A2 SLC11A1
10 copper ion transport GO:0006825 9.65 SLC11A2 HEPH CP
11 multicellular organismal iron ion homeostasis GO:0060586 9.65 SLC40A1 SLC11A2 SLC11A1 HFE HAMP
12 cellular response to iron ion GO:0071281 9.63 TFR2 TF HFE
13 response to vitamin A GO:0033189 9.62 HAMP EPO
14 positive regulation of bone resorption GO:0045780 9.62 TFRC TF
15 oxygen transport GO:0015671 9.61 HBB HBA2
16 response to hyperoxia GO:0055093 9.61 MT-CYB EPO
17 intestinal absorption GO:0050892 9.6 IREB2 ACO1
18 manganese ion transport GO:0006828 9.59 SLC11A2 SLC11A1
19 manganese ion transmembrane transport GO:0071421 9.58 SLC11A2 SLC11A1
20 positive regulation of peptide hormone secretion GO:0090277 9.58 TFR2 HFE
21 cadmium ion transmembrane transport GO:0070574 9.56 SLC11A2 SLC11A1
22 citrate metabolic process GO:0006101 9.55 IREB2 ACO1
23 response to iron ion starvation GO:1990641 9.54 HFE HAMP
24 regulation of iron ion transport GO:0034756 9.52 TF HFE
25 cellular iron ion homeostasis GO:0006879 9.5 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1

Molecular functions related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.26 TF MT-CYB IREB2 HEPH HBB HBA2
2 metal ion transmembrane transporter activity GO:0046873 9.58 SLC11A2 SLC11A1
3 oxygen carrier activity GO:0005344 9.57 HBB HBA2
4 co-receptor binding GO:0039706 9.56 TFR2 HFE
5 ferric iron binding GO:0008199 9.55 TF FTL
6 organic acid binding GO:0043177 9.54 HBB HBA2
7 haptoglobin binding GO:0031720 9.51 HBB HBA2
8 ferroxidase activity GO:0004322 9.49 HEPH CP
9 manganese ion transmembrane transporter activity GO:0005384 9.48 SLC11A2 SLC11A1
10 ferrous iron transmembrane transporter activity GO:0015093 9.46 SLC40A1 SLC11A2
11 cadmium ion transmembrane transporter activity GO:0015086 9.43 SLC11A2 SLC11A1
12 aconitate hydratase activity GO:0003994 9.4 IREB2 ACO1
13 transition metal ion transmembrane transporter activity GO:0046915 9.37 SLC11A2 SLC11A1
14 ferrous iron binding GO:0008198 9.33 TF HEPH FTL
15 iron-responsive element binding GO:0030350 9.32 IREB2 ACO1
16 transferrin receptor activity GO:0004998 9.26 TFRC TFR2
17 transferrin receptor binding GO:1990459 9.13 TF HJV HFE
18 iron ion transmembrane transporter activity GO:0005381 8.8 SLC40A1 SLC11A2 SLC11A1

Sources for Iron Metabolism Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....